Table 1.
Correlation of PLZF expression with the clinicopathological features of GBC
PLZF (high) | PLZF (low) | P-value | |||
---|---|---|---|---|---|
N = 31 | % | N = 49 | % | ||
Sexual | 0.249 | ||||
Male | 7 | 8.8 | 17 | 21.2 | |
Female | 24 | 30.0 | 32 | 40.0 | |
Age (years) | 0.702 | ||||
<65 | 14 | 17.5 | 20 | 25.0 | |
≥65 | 17 | 21.3 | 29 | 36.2 | |
Tumor size (cm) | 0.444 | ||||
<4 | 16 | 20.0 | 21 | 26.2 | |
≥4 | 15 | 18.8 | 28 | 35.0 | |
Differential grade | 0.851 | ||||
I–II | 19 | 23.8 | 29 | 36.2 | |
III–IV | 12 | 15.0 | 20 | 25.0 | |
TNM stage | 0.012* | ||||
I–II | 19 | 23.8 | 16 | 20.0 | |
III–IV | 12 | 15.0 | 33 | 41.2 | |
Lymph node metastasis | 0.102 | ||||
No | 26 | 32.5 | 33 | 41.2 | |
Yes | 5 | 6.3 | 16 | 20.0 | |
Distant metastasis | 0.008* | ||||
No | 25 | 31.3 | 25 | 31.2 | |
Yes | 6 | 7.5 | 24 | 30.0 |
χ2 test was performed
P < 0.05 was considered statistically significant, * P < 0.05.